The Complix management team

Dr. Mark Vaeck

Chief Executive Officer

Mark Vaeck has more than 30 years of experience in the biotech and pharma industry. As a serial entrepreneur he raised more than €100 million in equity financing for the biotech companies he helped creating.

In 2008, he co-founded Complix and was appointed CEO in May 2010. Prior to this, in 2006, Mark co-founded ActoGeniX (Belgium) and served as its CEO until 2010. He was also the founding CEO of Ablynx (Belgium) from 2001 until 2006. Before joining Ablynx, Mark was COO of Ceres Inc. (US), a NASDAQ listed company developing innovative technologies for biofuel production.

From 1987 to 1998, he held several business development and general management positions in the biotech and pharma industry, including at UCB, Chiron, Keygene and PGS.

Mark holds a PhD in Immunology from the Free University of Brussels.

Dr. Ignace Lasters

Chief Technology Officer

Ignace Lasters has over 35 years of experience in the life sciences industry. In 2008, Ignace co-founded Complix and was appointed as its first CEO. Ignace now assumes the role of CTO at Complix.

Ignace co-founded Algonomics, a bioinformatics company dedicated to immunogenicity analysis and antibody engineering, and acted as its CEO/CSO from 1999-2008, until it was acquired by Lonza. From 1986 to 1994, he held research group leader positions in several biotech companies. From 1995 to 1998 Ignace acted as a consultant in bioinformatics for major companies in the agro and life sciences industries.

Ignace holds a PhD in Biochemistry from the Free University of Brussels. He is the inventor on numerous patent applications. Ignace has a rich publishing track record of peer-reviewed articles in a variety of fields ranging from theoretical biology, computer modelling algorithms, scaffold design, to protein engineering and drug discovery.

Complix Cell Penetrating Alphabodies

A new revolutionary class of therapeutics targeting intracellular targets